4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2025)
Historic Change in Account Payables for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$1.8 million.
- 4D Molecular Therapeutics' Change in Account Payables fell 26161.42% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 33460.39%. This contributed to the annual value of $871000.0 for FY2024, which is 279.02% down from last year.
- 4D Molecular Therapeutics' Change in Account Payables amounted to -$1.8 million in Q3 2025, which was down 26161.42% from $4.5 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Change in Account Payables ranged from a high of $4.5 million in Q2 2025 and a low of -$1.8 million during Q3 2025
- Its 5-year average for Change in Account Payables is $257421.1, with a median of $226000.0 in 2022.
- In the last 5 years, 4D Molecular Therapeutics' Change in Account Payables plummeted by 31345.91% in 2022 and then skyrocketed by 67875.32% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Change in Account Payables stood at $1.7 million in 2021, then dropped by 8.97% to $1.5 million in 2022, then plummeted by 171.91% to -$1.1 million in 2023, then surged by 234.38% to $1.5 million in 2024, then crashed by 225.65% to -$1.8 million in 2025.
- Its Change in Account Payables stands at -$1.8 million for Q3 2025, versus $4.5 million for Q2 2025 and -$235000.0 for Q1 2025.